The Scottish Medicines Consortium has said no for Kyntheum (aka Brodalumab / Silq ) in the treatment of psoriasis.

A short statement read:

Quote:

---

The committee was unable to accept brodalumab (Kyntheum) for the treatment of moderate to severe plaque psoriasis, a condition which causes red scaly patches on the skin, because of uncertainties in the case made by the submitting company

Source: scottishmedicines.org.uk

Kyntheum / Siliq (brodalumab)

Well... to my strong opinion, that is quite an uncertain explanation....

(Tue-12-12-2017, 14:00 PM)Caroline Wrote: Well... to my strong opinion, that is quite an uncertain explanation....  

Well it's to the point. It means that LEO Pharma have not answered their questions.

So it doesn't need much more to be said really, plus don't forget all the talk about Suicide that has plagued this treatment. Maybe they wanted more answers on that, but whatever it was they are not happy so have refused it.

(Tue-12-12-2017, 14:06 PM)Fred Wrote:

(Tue-12-12-2017, 14:00 PM)Caroline Wrote: Well... to my strong opinion, that is quite an uncertain explanation....  

Well it's to the point. It means that LEO Pharma have not answered their questions.

So it doesn't need much more to be said really, plus don't forget all the talk about Suicide that has plagued this treatment. Maybe they wanted more answers on that, but whatever it was they are not happy so have refused it.

But that is a guess of you.
They talk about uncertainties, but don't tell which uncertainties, I do not feel that as being to the point.
To the point would be:
1. We have heard about suicide, can you explain that? (I imagine they can't, so the answer is: "NO")
2. Whatever.... no
3. Whatever 2 .... no
4. Whatever 3 .... no

that is what I call to the point.

(Tue-12-12-2017, 14:38 PM)Caroline Wrote: But that is a guess of you.

Exactly that is why I said  "Maybe".

All I know is they said "because of uncertainties in the case made by the submitting company" and that to me says that it's a private thing between the two parties. It's none of our business as to what the questions where, it's a matter between the regulator and the manufacturer.